Rofecoxib

Vioxx Withdrawl and Biologic litigation

On Sept. 30, 2004 Merck appear a common abandonment of Vioxx® (rofecoxib). Vioxx had ahead been assigned in the analysis of arthritis and pain. Common sales of Vioxx in 2003 were an estimated $2.5Billion and the biologic was marketed in added than 80 countries about the world. This is one of several contempo biologic articles to accept been put in the spotlight by both the civic media and plaintiff lawyers.

Since ancient in the mid to backward 90s a abundant cardinal of biologic medications and medical accessories accept been removed from the bazaar due to accessible adverse bloom implications. The FDA acts as a authoritative anatomy in acknowledging bloom accompanying articles afore they are marketed to consumers. The FDA confused to ban Ephedra in the US in 2004. However, the contempo account about autonomous biologic withdrawals accept produced questions as to the FDA's contempo performance.
Rofecoxib


Many bodies accept that the FDA did not analysis the drugs anxiously abundant to actuate all the accessible bloom problems that they ability cause. Bodies accept that the acceleration in action over these medications was due to the actuality that the FDA now allows biologic companies to “fast track” their articles and get them through the action in a year. In fact, Vioxx was alone appear in 1999.

Some of the latest drugs area apropos accept additionally arose are Bextra, Celebrex and Zyprexa. Action over these drugs may appear in the abreast future. US plaintiff attorneys accept amorphous to put some austere time and analysis into accessible claims that may appear from biologic drugs. Plaintiff attorneys additionally handle Mesothelioma, Car Accident, and a advanced array of altered claimed abrasion cases.

If you anticipate that you may accept been afflicted by one of these drugs that accept afresh fabricated headlines, you may accede consulting with a lawyer. Many plaintiff attorneys handle cases on a accident basis.